CA-170 is under clinical development by Aurigene Discovery Technologies and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CA-170’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 19 Aug 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CA-170 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CA-170 overview

CA-170 is under development for the treatment of advanced solid tumors include malignant pleural mesothelioma, melanoma, renal cell carcinoma, triple-negative breast cancer, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, Hodgkin lymphoma (B-cell Hodgkin lymphoma), head and neck cancer squamous cell carcinoma, endometrial cancer, colorectal cancer, gastric cancer, bile duct cancer (cholangiocarcinoma) and bladder cancer, and ovarian cancer. It is a small molecule administered through oral route. It is an immune check point inhibitor and acts by targeting PD-L1, TIM3 and V-domain Ig suppressor of T cell activation (VISTA). It was also under development for colorectal cancer, Hodgkin lymphoma (B-cell Hodgkin lymphoma), gastric cancer, endometrial cancer, bile duct cancer (cholangiocarcinoma), non-small cell lung cancer, head and neck cancer squamous cell carcinoma, squamous non-small cell lung cancer.

Aurigene Discovery Technologies overview

Aurigene Discovery Technologies (Aurigene), a subsidiary of Dr. Reddy’s Laboratories Ltd, is a biotechnology company that develops small molecule and peptide therapeutics. The company develops small molecule and peptide drug candidates for oncology and inflammatory diseases. It owns integrated drug discovery infrastructure from hit generation to pre-clinical development. Aurigene’s pipeline portfolio consists of products for immunoncology PD-L1 and Vista, TIM-3 and PD1, CD47; precision oncology products IRAK4, NAMPT, KRAS, CDK7; Epigenetics products BET Bromodomain, PRMT5, CBP and P300; and inflammatory product ROR Inverse Agonist. It operates through collaboration with mid-pharma companies. Aurigene is headquartered in Bangalore, Karnataka, India.

Quick View CA-170 LOA Data

Report Segments
  • Innovator
Drug Name
  • CA-170
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.